MITRA-FR: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation

Courtesy of Dr. Adolfo Ferrero.

INTRODUCCION: In patients with chronic heart failure and reduced left ventricular ejection fraction, severe secondary mitral valve regurgitation is associated with bad prognosis. Whether percutaneous mitral valve repair improves clinical results in this patient population, remains unclear, despite prior multicenter studies supporting this view.

METHODS: Patients with severe secondary mitral valve regurgitation (defined as an effective regurgitant orifice area of >20 mm2 or a regurgitant volume of >30 ml per beat), left ventricular ejection fraction between 15 and 40%, and symptomatic heart failure, were randomized 1:1 to percutaneous mitral-valve repair in addition to medical therapy (intervention group; 152 patients) vs. medical therapy alone (control group; 152 patients). Primary efficacy end point was a composite of all cause death or unplanned hospitalization for heart failure at 12 months.

 

RESULTS: At 12 months, primary end point was 54.6% (83 of 152 patients) in the intervention group and 51.3% (78 of 152 patients) in the control group (OR 1.16; 95% CI, 0.73 to 1.84; P=0.53). All cause death was 24.3% (37 of 152 patients) in the intervention group and 22.4% (34 of 152 patients) in the control group (HR 1.11; 95% CI, 0.69 to 1.77). Unplanned hospitalization for heart failure was 48.7% (74 of 152 patients) in the intervention group and 47.4% (72 of 152 patients) in the control group (HR 1.13; 95% CI, 0.81 to 1.56).


Read also: Antiaggregation Time after Treating Bifurcations.


CONCLUSIONS: Among patients with severe secondary mitral regurgitation, death or unplanned hospitalization rates for heart failure at 1 year did not differ significantly between patients undergoing percutaneous mitral-valve repair and medical therapy, and those who received medical therapy alone.

 

Courtesy of Dr. Adolfo Ferrero.

 

Original title: Percutaneous Repair or Medical Treatmentfor Secondary Mitral Regurgitation.

Reference: J.-F. Obadia, Et Al. For the MITRA-FR Investigators. NEJM DOI: 10.1056/NEJMoa1805374.

MITRA-FR: Reparación percutánea o tratamiento médico para la insuficiencia mitral secundaria

MITRA-FR


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...